BCYC News and Press, Bicycle Therapeutics plc From 03/01/22

Bicycle Therapeutics press release (NASDAQ:BCYC): Q4 GAAP EPS of -$0.63 beats by $0.01. Revenue of $3.77M (-2.1% Y/Y) misses by $1.11M. For further details see: Bicycle Therapeutics GAAP EPS of -$0.63 beats by $0.01, revenue of $3.77M misses by $1.11M

- Continued clinical progress across pipeline of Bicycle Toxin Conjugates ® (BTCs) and Bicycle tumor-targeted immune cell agonists ( Bicycle TICAs) - Cash of $438.7 million at December 31, 2021 expected to provide financial runway through 2024 Bicycl...

BT8009 test results conformed to preliminary data suggesting it to be an effective treatment for tumors. BT7480 is currently advancing its phase I clinical trials, and CEO Dr. Kevin Lee said he is pleased with the progress. Bicycle recently reached a partnership with both Roche an...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that management will participate in a fireside chat at the 11 th Ann...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced continued progress in its ongoing Phase I/II clinical trials of BT8...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While this isn’t the end of giant pharmaceutical companies, there is a new generation of biotechs that have been able to advance rapidly due to the massive advances in computer technology in recent decades. These A-r...

Bicycle Therapeutics plc (NASDAQ:BCYC) traded today at a new 52-week high of $62.19. So far today approximately 105,000 shares have been exchanged, as compared to an average 30-day volume of 449,000 shares. Bicycle Therapeutics plc (NASDAQ:BCYC) defies analysts with a current price ($60....

Positive interim data was achieved using BT5528 for the treatment of patients with advanced solid tumors. Positive preliminary data was achieved using BT8009 for the treatment of patients with advanced solid tumors. I believe that the addition of Opdivo for each BT8009 and BT5528 ...

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that preclinical data for BT7480, a novel Bicycle tumor-targeted imm...

Bicycle Therapeutics (NASDAQ:BCYC): Q3 GAAP EPS of -$0.59 beats by $0.03. Revenue of $4.33M (+12.8% Y/Y) misses by $1.42M. Press Release For further details see: Bicycle Therapeutics EPS beats by $0.03, misses on revenue